Showing results (1521-1530 of 1,809) with videos related to
Sort By:
Pageof 181
Plos One|March 20, 2010
A novel translocation breakpoint within the BPTF gene is associated with a pre-malignant phenotypeYosef Buganim, Ido Goldstein, Doron Lipson, et al.Spine|June 17, 2026
The Role of L4-L5 Facet Joint and Disc-Related Anatomy in Lumbar Spondylolisthesis: An Imaging StudyMaxey Cherel, Aiyush Bansal, Takeshi Fujii, et al.Eating Behaviors|May 28, 2021
Characterizing eating disorder diagnosis and related outcomes by sexual orientation and gender identity in a national sample of college studentsAnne Claire Grammer, Melissa M Vázquez, Ellen E Fitzsimmons-Craft, et al.Human Molecular Genetics|May 1, 2016
ERK1/2 directly acts on CTGF/CCN2 expression to mediate myocardial fibrosis in cardiomyopathy caused by mutations in the lamin A/C geneMaria Chatzifrangkeskou, Caroline Le Dour, Wei Wu, et al.Oncogene|April 6, 2004
The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variantsSylvie Berthou, Daniel M Aebersold, Laura S Schmidt, et al.ACS Chemical Neuroscience|January 22, 2013
Synergism between a serotonin 5-HT2A receptor (5-HT2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addictionKathryn A Cunningham, Noelle C Anastasio, Robert G Fox, et al.Psychopharmacology|March 4, 2008
Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disordersSarah K Leonard, Jason M Dwyer, Stacey J Sukoff Rizzo, et al.Journal of Pharmacological and Toxicological Methods|January 6, 2009
Flow cytometric analysis of BrdU incorporation as a high-throughput method for measuring adult neurogenesis in the mouseDarrick T Balu, Georgia E Hodes, Tiffany E Hill, et al.The Journal of Pharmacology and Experimental Therapeutics|March 16, 2011
Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonistJohn Dunlop, Stephanie W Watts, James E Barrett, et al.Case Reports in Oncology|September 19, 2014
Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown PrimaryNorma A Palma, Siraj M Ali, Jamie O'Connor, et al.Pageof 181